# Cutaneous Neurofibroma Working Group

## Ashley Cannon, PhD, MS, CGC Dominique Pichard, MD

### Ashley Cannon, PhD, MS, CGC



- Neuroscientist and Certified Genetic Counselor
- UAB, Dept. of Genetics
- cNF quantitative natural history
- Methylation, transcriptomic, and genomic alterations associated with cNF growth
- Selumetinib clinical trial targeting cNF



## Dominique Pichard, MD



- Dermatologist
- NCI, Dermatology Branch
- cNF Selumetinib clinical trial targeting cNF
- 3D photography and HFUS for measuring cNF volume and size



## cNF Working Group Members (to date)

#### Dermatology

- Dominique Pichard, NIH
- Pierre Wolkenstein, Henri-Mondor Hospital
- Lu Le, UTSW

#### Neurology

- Kaleb Yohay, NYU
- Victor-Felix Mautner,
  University Medical Center
  Hamburg-Eppendorf,
  Germany

#### R&D



Sharad Verma, NTAP

#### Genetics

Ashley Cannon, UAB

#### Neuro-oncology

- Michael Fisher, CHOP
- Scott Plotkin, MGH
- Chie-Schin Shih, Riley
  Children's
- Jaishri Blakeley, JHH

#### Neuropathology

Anat Stemmer-Rachamimov

#### Pediatric Oncology

Brigitte Widemann, NIH

## cNF Working Group Goals

- Identify additional group members
- Establish monthly group meetings
- Develop project ideas



## cNF Working Group Goals

- Goals of the cNF working group to include:
  - 1) Identification of research priorities for cutaneous neurofibromas
  - 2) The development of recommendations for
    - clinical trial endpoints
    - clinical trial designs
    - outcome measures for clinical trials



#### **Contact Information**

 Ashley Cannon: <u>ashleycannon@uabmc.edu</u>

 Dominique Pichard: dominique.pichard@nih.gov

https://ccrod.cancer.gov/confluence/display/REINS/Cutaneous+Neurofibromas

